Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
59 hedge funds and large institutions have $104M invested in Strongbridge Biopharma plc. in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 24 reducing their positions, and 33 closing their positions.
283% more call options, than puts
Call options by funds: $625K | Put options by funds: $163K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
10% more capital invested
Capital invested by funds: $94.3M → $104M (+$9.76M)
20% less funds holding
Funds holding: 74 → 59 (-15)
45% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 33
50% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$7.55M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$7.12M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$4.04M |
| 4 |
E
Ergoteles
New York
|
+$2.89M |
| 5 |
Man Group
London,
United Kingdom
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$6.06M |
| 2 |
BlackRock
New York
|
-$5.22M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.2M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.83M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.73M |
SBBP Hedge Fund Activity: Q2 2021 in Review
59 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q2 2021, worth a combined $104M — up 10% from $94.3M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of SBBP and 18 opened new positions — a net loss of 15 holders — while 24 trimmed existing stakes and 12 added.
The largest buyer was Stonepine Capital Management, adding an estimated $7.55M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $6.06M sold.
- 59 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q2 2021, down from 74 in Q1 2021.
- Funds reported $104M of Strongbridge Biopharma plc. stock for Q2 2021, up 10% quarter-over-quarter.
- 18 funds opened new Strongbridge Biopharma plc. positions in Q2 2021 and 33 closed out, a net change of -15 holders.
- The largest Strongbridge Biopharma plc. buyer in Q2 2021 was Stonepine Capital Management, an estimated $7.55M added.
- The largest Strongbridge Biopharma plc. seller in Q2 2021 was AIGH Capital Management, an estimated $6.06M sold.
Based on aggregated 13F filings for Q2 2021.